Track Anteris Technologies Ltd — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Anteris Technologies Ltd AVR.AX · Stock Open Anteris Technologies Ltd in new tab

11.68 AUD
EPS
-2.75
P/B
3.27
ROE
-74.65
Beta
0.73
Loading chart...
Key Metrics
Earnings dateAug. 17, 2026
EPS-2.75
Book Value3.61
Price to Book3.27
Debt/Equity1.32
% Insiders0.163%
Growth
Revenue Growth0.63%
Estimates
Forward P/E-5.45
Forward EPS-2.17

DCF Valuation

Tweak assumptions to recompute fair value for Anteris Technologies Ltd (AVR.AX)
Currency: AUD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Anteris Technologies Ltd Logo Anteris Technologies Ltd Analysis (AVR.AX)

Australia Health Care Official Website Stock

Is Anteris Technologies Ltd a good investment? Anteris Technologies Ltd (AVR.AX) is currently trading at 11.68 AUD.

Earnings Schedule: Anteris Technologies Ltd is expected to release its next earnings report on Aug. 17, 2026. The market consensus estimate for Forward EPS is -2.17.

Investor FAQ

Does Anteris Technologies Ltd pay a dividend?

No, it does not currently pay a dividend.

What asset class is Anteris Technologies Ltd?

Anteris Technologies Ltd is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 17, 2026. The company currently has a trailing EPS of -2.75.

Company Profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Exchange Ticker
ASX (Australia) AVR.AX
PNK (United States) AMEUF
Trades
Dividend History paid per year (AUD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Feb. 23, 2009 1.21
Sept. 25, 2013 1.06
March 24, 2015 1.02
Nov. 17, 2015 1:10
March 2, 2020 1:100
March 12, 2020 1:100
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion